NexGel Bets Big With Transformational Acquisition And Financing

Nexgel, Inc. ((NXGL)) has held its Q4 earnings call. Read on for the main highlights of the call.

NexGel’s latest earnings call blended optimism with caution as management unveiled a transformational acquisition that could roughly triple revenue while immediately boosting profitability. Executives emphasized the expanded commercial footprint and strategic partnerships, but investors also heard frank discussion of dilution risk, seasonal volatility, and the challenge of restarting a disrupted salesforce.

Transformational Acquisition and Revenue Upside

NexGel has closed the purchase of Celularity’s degenerative wound segment, which management says nearly triples its annual revenue run rate to about $35 million. Leadership stressed that the deal should be immediately accretive to profitability, positioning the company on a much larger operating base than its legacy hydrogel platform alone.

Strategic Financing and Partnership with Sequence LifeScience

The deal is anchored by a $5.5 million strategic investment from Sequence LifeScience, including cash and convertible notes at a $0.60 conversion price plus warrants at $0.80. Beyond capital, Sequence becomes a manufacturing and development partner, offering backup production capacity and broader distribution capabilities to support NexGel’s expanded portfolio.

Commercial-Stage Product Portfolio and Market Access

NexGel now controls six established regenerative biomaterial products that have been in clinical use for more than a decade and are already reimbursed. These products are used in roughly 500 hospitals, giving the company immediate access to a large installed base and recurring revenue streams that would have taken years to build organically.

Near-Term Pipeline and R&D Assets

The acquisition brings three existing 510(k) devices in the pipeline, supported by $4.6 million of paid-in capital scheduled between 2026 and 2028. NexGel also gains R&D staff, lab space, and patent ownership for future programs such as FUSE and ORCHID, tightening control over innovation and timelines.

Profitability and Margin Profile

Management outlined a pro forma blended contribution margin of about 52 percent after cost of goods and sales commissions. With fixed overhead modeled at roughly $6.0 to $6.5 million, the company believes a $22 to $23 million revenue run rate could yield $4.0 to $4.5 million of EBITDA and support sustained profitability once integration is complete.

Experienced Commercial Team and Fast Transition

The transaction includes an experienced commercial and scientific team that largely remains in the same facility via a sublease, enabling a quick handoff of operations. Management noted that sales under the NexGel umbrella restarted the Monday before the call, signaling minimal downtime for revenue-generating activities.

Q4 Underperformance and Seasonality Risk

Despite the upbeat deal narrative, NexGel admitted that fourth quarter results were materially below guidance, with several new consumer products falling short. The business is also seasonal, with first quarter the weakest and third and fourth quarters the strongest, adding cash-flow timing risk just as the company works to reignite sales momentum.

Complex and Dilutive Financing Structure

The financing package involves 18‑month convertible notes carrying a 10 percent coupon and 50 percent warrant coverage, which could significantly expand the share count if converted. Management’s own example suggested roughly 2.4 million shares per $1 million raised and an overall deal raise of $12 to $14 million that could add on the order of tens of millions of shares.

Immediate Cash Obligations and Legacy Issues

NexGel paid $5.3 million at closing and assumed about $2.9 million of unpaid commissions owed to Celularity’s sales representatives, some of whom are reinvesting. These legacy liabilities highlight the prior financial stress of the acquired business and require fresh capital to repair relationships and fully reengage the field force.

Sales Commission Pressure in Surgical Channel

The company described a three-tier margin structure, noting that surgical products carry attractive pricing but commissions that can reach 30 to 40 percent. This leaves NexGel balancing lower-margin distributor sales, mid-margin wound care, and high-margin but commission-heavy surgical volume to maintain its targeted blended contribution margin.

Market Skepticism and Execution Risk

Management acknowledged initial negative reaction from investors, reflecting concerns about integration and the financing overhang. Success will depend on rehiring and motivating sales reps, harmonizing teams, and scaling commercial efforts back toward historical peaks that once approached $50 million of annual sales for the acquired assets.

Outlook and Forward-Looking Guidance

Looking ahead, NexGel expects pro forma revenue to reach about $35 million and to be accretive to profitability, with a goal of achieving EBITDA positivity by the quarter ending September 30. The company reiterated its 52 percent contribution margin target and believes that as it approaches a $22 to $23 million revenue run rate, it can generate several million dollars of annual EBITDA despite seasonality and commission drag.

NexGel’s earnings call painted a picture of a small company making a big bet, trading dilution and execution risk for a step-change in scale and product breadth. Investors will be watching closely to see if management can stabilize the acquired business, manage its complex capital structure, and convert this transformational deal into sustainable growth and consistent profitability.